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Abstract
Background: Proteinuria is a target for renoprotection in kidney diseases. However, optimal level of proteinuria reduction in
IgA nephropathy (IgAN) is unknown.
Methods: We conducted a retrospective observational study in 500 patients with biopsy-proven IgAN. Time-averaged
proteinuria (TA-P) was calculated as the mean of every 6 month period of measurements of spot urine protein-to-creatinine
ratio. The study endpoints were a 50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal
disease (ESRD), and slope of eGFR.
Results: During a median follow-up duration of 65 (12–154) months, a 50% decline in eGFR occurred in 1 (0.8%) patient with
TA-P of ,0.3 g/g compared to 6 (2.7%) patients with TA-P of 0.3–0.99 g/g (hazard ratio, 2.82; P= 0.35). Risk of reaching a
50% decline in eGFR markedly increased in patients with TA-P of 1.0–2.99 g/g (P= 0.002) and those with TA-P$3.0 g/g (P,
0.001). ESRD did not occur in patients with TA-P,1.0 g/g compared to 26 (20.0%) and 8 (57.1%) patients with TA-P of 1.0–
2.99 and $3.0 g/g, respectively. Kidney function of these two groups deteriorated faster than those with TA-P,1.0 g/g (P,
0.001). However, patients with TA-P of 0.3–0.99 g/g had a greater decline of eGFR than patients with TA-P,0.3 g/g (2
0.4161.68 vs. 20.7362.82 ml/min/1.73 m2/year, P= 0.03).
Conclusion: In this study, patients with TA-P,1.0 g/g show favorable outcomes. However, given the faster eGFR decline in
patients with TA-P of 0.3–0.99 g/g than in patients with TA-P,0.3 g/g, the ultimate optimal goal of proteinuria reduction
can be lowered in the management of IgAN.
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Introduction
IgA nephropathy (IgAN) is slowly progressive and 20–30% of
patients with IgAN will require renal replacement therapy within
20–25 years after disease onset [1,2]. Because it is not a totally
benign condition, a number of studies have identified risk factors
associated with progression of IgAN. Among these, proteinuria is
considered a strong predictor of adverse renal outcome [3–13]. In
fact, proteinuria is significantly related to clinical and pathological
factors that affect the future outcome in many glomerular diseases;
thus is a therapeutic target for kidney protection. Treatment
options for achieving reducing proteinuria differ according to the
type and severity of disease. As aforementioned, unlike idiopathic
nephrotic syndrome or crescentic glomerulonephritis showing
abrupt onset or a rapidly progressive decline in renal function,
IgAN is characterized by slowly progressive nature without
symptoms over time. Therefore, it is difficult to determine when
to treat or who should be treated. In addition, therapeutic options
are limited and the role of immunosuppressive drugs has not yet
been clearly defined. Nevertheless, reducing proteinuria is of
paramount importance to improve prognosis in these patients.
However, the optimal target for proteinuria reduction to attenuate
progression of kidney disease is currently unknown. Interestingly,
the target may differ depending on the type of proteinuric
glomerular disease [14]. Moreover, although a favorable outcome
is more likely for patients with IgAN that have proteinuria ,1 g/
day throughout the disease course, there is controversy on whether
further reduction of proteinuria below this level will provide
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additional benefit [11,12]. The purpose of this study was,
therefore, to identify the optimal target for proteinuria reduction
for renoprotection in patients with IgAN. To this end, we used
time-averaged proteinuria (TA-P) and classified patients into four
groups according to TA-P levels. In particular, we aimed to
investigate whether reducing proteinuria below the level that the
current guideline suggests may improve renal outcome.
Materials and Methods
Patient Selection
A flow chart of participants is shown in Figure 1. A total of 644
patients were pathologically diagnosed with IgAN in Yonsei
University Severance Hospital and National Health Insurance
Services Ilsan Hospital between 2002 and 2010. All patients had
definite pathologic findings with predominant mesangial deposi-
tion of IgA with at least 1+ on immunofluorescent staining and
electron-dense deposits within the mesangium detected by electron
microscopy. Patients with Henoch-Schonlein purpura nephritis
were considered ineligible. Exclusion criteria were as follows: aged
,18 years (n = 18); follow-up duration ,12 months (n = 89);
inadequate biopsy sample containing #7 glomeruli (n = 13);
secondary causes of mesangial IgA deposition, such as IgA-
dominant acute post-infectious glomerulonephritis (n = 4); systemic
lupus erythematosus (n = 8); liver cirrhosis (n = 7); or malignancy
(n = 5). Therefore, a total of 500 patients were analyzed in this
study. We carried out the study in accordance with the
Declaration of Helsinki, and the study was approved by the
Institutional Review Board (IRB) of Yonsei University Health
System Clinical Trial Center. Since the current study was a
retrospective study and the study subjects were de-identified, the
IRB waived the need for written consent from the patients.
Data collection
Demographic and clinical data were collected at the time of
renal biopsy. These included gender, age, systolic and diastolic
blood pressure (BP), comorbidities, date of renal biopsy, pathologic
findings, and laboratory parameters. Estimated glomerular filtra-
tion rate (eGFR) was calculated using the CKD-EPI equation [15].
During follow-up, proteinuria was assessed by spot urine protein-
creatinine ratio (UPCR) because measurement of 24-h protein
excretion was not feasible at all visits. Using these data, we
calculated TA-P as an average of the means of every 6 month
period of proteinuria measurements [11]. TA-BP was also
determined in the same way. In addition, medications including
anti-hypertensives, renin-angiotensin system (RAS) blockers, and
immunosuppressants were recorded. In this study, we presented
pathologic findings using the Oxford classification criteria [16,17].
We also determined the absolute renal risk (ARR) score at the
time of diagnosis as suggested by Berthoux et al [4]. ARR was
scored from 0 to 3 depending on the number of risk factors; (1) the
presence of hypertension, (2) proteinuria $1.0 g/g, and (3) renal
pathologic lesion. For renal lesion, instead of global optical score
used in the original study by Berthoux et al, MEST score was
determined using the sum of each lesion by the Oxford
classification. We performed ROC analyses and found that MEST
score $2.0 had the highest AUC value (0.744), thus was
considered as a score of 1 for pathologic lesion. We evaluated
the effect of proteinuria reduction according to each score of
ARR.
Study endpoints
Study endpoints were a 50% decline in eGFR, the onset of end-
stage renal disease (ESRD), and slope of eGFR. A 50% decline in
eGFR was defined as a sustained decrease in eGFR.50% for at
least three consecutive measurements. The first of these consec-
utive measurements was retrospectively designated to be the 50%
decline in eGFR endpoint. ESRD was defined as initiation of
dialysis or receipt of a transplant.
Statistical Analyses
All variables with normal distribution were expressed as mean
6 standard deviation. Comparisons were made by Student’s t-tests
or one-way ANOVA for continuous variables and by the Chi-
square test for categorical variables as required. If data did not
have a normal distribution, they were expressed as median and
interquartile range and were compared using the Mann–Whitney
test or the Kruskal–Wallis test. The cumulative renal survival rates
were estimated by the Kaplan-Meier method and differences
between survival curves were compared with the log-rank test.
Figure 1. Flow chart of participants. Abbreviations: IgAN, Immunoglobulin A nephropathy; SLE, systemic lupus erythematosus; TA-P, time-
averaged proteinuria.
doi:10.1371/journal.pone.0101935.g001
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Renal survival time was defined as the interval between the time of
biopsy and last follow-up. We determined the slope of the eGFR
decline using multiple linear regression analyses. A Cox propor-
tional hazards model was used to identify independent variables
affecting renal survival. Variables with a p-value,0.10 in the
univariate analysis were entered into the multivariate analysis. The
results were expressed as a hazard ratio (HR) and 95% confidence
interval (CI). All P-values were two-tailed and values ,0.05 were
considered statistically significant. Data analysis was performed
using SPSS version 18 software for Windows (SPSS, Chicago, IL).
Table 1. Patient characteristics according to time-averaged proteinuria.
Time-averaged proteinuria (g/g)
Variables Total ,0.3 0.3–0.99 1.0–2.99 $3.0 P-for trend
Number 500 130 (26.0%) 226 (45.2%) 130 (26.0%) 14 (2.8%)
Male (n, %) 215 (43%) 76 (58.5%) 85 (37.6%) 50 (38.5%) 10 (28.6%) 0.01*
Age (years) 37.1612.0 34.2612.3 38.0611.6 38.4612.0 35.6611.4 0.08
Hypertension (n, %) 122 (24.4%) 21 (16.2%) 59 (26.1%) 38 (29.2%) 4 (28.6%) 0.06*
Hypertension at last follow-up (n, %) 178 (35.6%) 33 (25.4%) 77 (34.1%) 61 (46.9%) 7 (50.0%) 0.002*
TA-SBP (mmHg) 121.568.5 120.368.0 120.768. 5 123.668.6 126.468.9 ,0.001
TA-DBP (mmHg) 75.566.4 74.165.9 75.266.5 77.066.3 78.166.0 ,0.001
TA-MAP (mmHg) 90.866.6 89.566.0 90.466.8 92.566.6 94.265.9 ,0.001
BUN (mg/dl) 15.065.7 13.263.9 14.965.1 16.866.9 17.969.5 ,0.001
S-Cr (mg/dl) 1.060.4 1.060.3 1.060.3 1.160.5 1.260.6 ,0.001
eGFR (ml/min per 1.73 m2) 87.3628.5 89.0625.0 89.8626.3 81.8633.8 83.4635.5 0.04
eGFR stage (ml/min per 1.73 m2)
$90 (n, %) 241 63 (48.5%) 119 (52.7%) 53 (40.8%) 6 (42.9%) 0.18*
60–89 (n, %) 162 51 (39.2%) 70 (31.0%) 38 (29.2%) 3 (21.4%) 0.23*
30–60 (n, %) 84 15 (11.5%) 35 (15.5%) 30 (23.1%) 4 (28.6%) 0.05*
15–30 (n, %) 13 1 (0.8%) 2 (0.9%) 9 (6.9%) 1 (7.1%) 0.002*
Serum albumin (g/dl) 4.060.6 4.360.5 4.060.5 3.860.6 3.060.8 ,0.001
Total cholesterol (mg/dl) 190.0650.0 175.7646.0 186.1636.2 203.3661.7 235.2.9669.2 ,0.001
Triglyceride (mg/dl){ 110.0 (80.0–161.0) 98.0 (75.0–137.8) 104.5 (74.5–160.0) 127.5 (91.0–201.3) 130.0 (99.5–158.5) 0.001
Hb (g/dl) 13.162.0 13.761.4 13.261.9 13.062.2 10.263.0 ,0.001
UPCR (g/g){ 0.9 (0.4–1.8) 0.3 (0.1–0.6) 0.9 (0.5–1.4) 1.8 (1.1–3.0) 4.7 (2.9–6.1) ,0.001
Proteinuria (g/24 h){ 0.5 (0.1–1.5) 0.2 (0.1–0.4) 0.6 (0.1–1.2) 1.3 (0.8–2.9) 2.9 (1.1–4.4) ,0.001
Treatment (n, %)
RAS blockers 390 (78.0%) 66 (50.8%) 188 (83.2%) 123 (94.6%) 13 (92.9%) ,0.001*
Corticosteroids 55 (11.0%) 6 (4.6%) 25 (11.1%) 17 (13.1%) 7 (50.0%) ,0.001*
Fish oil 20 (4.0%) 5 (3.8%) 10 (4.4%) 3 (2.3%) 2 (14.3%) 0.176*
Oxford-MEST (n, %)
M1 205 (41.0%) 31 (23.8%) 91 (40.3%) 75 (57.7%) 8 (57.1%) ,0.001*
E1 48 (9.6%) 5 (3.8%) 22 (9.7%) 18 (13.8%) 3 (21.4%) 0.019*
S1 209 (41.8%) 29 (22.3%) 115 (50.9%) 61 (46.9%) 4 (28.6%) ,0.001*
T1 53 (10.6%) 3 (2.3%) 19 (8.4%) 27 (20.8%) 4 (28.6%) ,0.001*
T2 36 (7.2%) 1 (0.8%) 5 (1.0%) 26 (20.0%) 4 (28.6%) ,0.001*
MEST score 1.261.2 0.560.7 1.161.0 1.861.3 1.961.4 ,0.001
ARR score 1.061.0 0.460.7 1.060.9 1.660.9 1.860.8 ,0.001
0 (n, %) 184 (36.8%) 92 (50.0%) 74 (40.2%) 17 (9.2%) 1 (0.5%) ,0.001*
1 (n, %) 149 (29.8%) 25 (16.8%) 85 (57.0%) 36 (24.2%) 3 (2.0%) ,0.001*
2 (n, %) 132 (26.4%) 13 (9.8%) 53 (40.2%) 58 (43.9%) 8 (6.1%) ,0.001*
3 (n, %) 35 (7.0%) 0 (0.0%) 14 (6.2%) 19 (14.2%) 2 (14.3%) ,0.001*
All data are expressed as mean 6 SD or
{median (and interquartile range).
*Statistical analyses were done using chi-square tests.
Abbreviations: TA-SBP, time-averaged systolic blood pressure; TA-DBP, time-averaged diastolic blood pressure; TA-MAP, time-averaged mean arterial pressure; BUN,
blood urea nitrogen; S-Cr, serum creatinine; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; UPCR, urine protein-to-creatinine ratio; RAS, renin-angiotensin
system; ARR, absolute renal risk.
doi:10.1371/journal.pone.0101935.t001
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Results
Patient characteristics according to TA-P
Patient characteristics of the study population are shown in
Table 1. The mean age at the time of renal biopsy was 37.0612.0
years and 215 patients (43%) were male. 122 (24.4%) patients were
hypertensive before renal biopsy. The median 24-h protein
excretion was 0.5 (0.1–1.5) g/day and mean eGFR was
80.2623.4 ml/min/1.73 m2. When pathologic findings were
analyzed using the Oxford classification system, there were 205
(41.0%), 48 (9.6%), 209 (41.8%), 53 (10.6%) and 36 (7.2%)
patients with M1, E1, S1, T1, and T2 lesions, respectively.
Patients were categorized into four groups according to TA-P
(Table 1). 130 (26.0%), 226 (45.2%), 130 (26.0%), and 14 (2.8%)
patients had a TA-P of ,0.3, 0.3–0.99, 1.0–2.99, and $3.0 g/g,
respectively. There were no significant differences in age, sex, or
comorbidities, between the four groups. However, TA-BP, serum
concentrations of total cholesterol and triglycerides, 24-h urine
protein excretion, urine UPCR, MEST score, and ARR score
were significantly higher in patients with higher TA-P (P for trend
,0.001). eGFR (P for trend= 0.04) and serum albumin levels (P
for trend ,0.001) were lower in patients with higher TA-P.
During follow-up, patients with TA-P,0.3 g/g were less treated
with RAS blockers than other groups. In addition, corticosteroids
were most commonly prescribed to patients with TA-P$3.0 g/g.
Changes in eGFR, CKD stage, proteinuria, and BP during
follow-up
Median follow-up duration in the cohort was 65 (12–154)
months. Data for eGFR, CKD stage, proteinuria, and BP at the
time of diagnosis and last follow-up are presented in Table 2.
eGFR decreased from 87.3628.5 to 76.9632.8 ml/min per
1.73 m2. Accordingly, there were more patients with higher
CKD stages at last follow-up. Proteinuria decreased from 0.9 (0.4–
1.8) to 0.4 (0.1–1.0) g/g during this period. At the time of
diagnosis, 122 (24.4%) patients had hypertension. Baseline systolic
and diastolic blood pressures of these patients were 136.7618.2
and 84.0611.9 mmHg, respectively. During the follow-up period,
56 (11.2%) patients newly developed hypertension. Of 110
hypertensive patients with TA-P,1.0 g/g, 61 (55.5%) achieved
BP#130/80 mmHg. In addition, 12 (17.6%) patients of 68
hypertensive patients with TA-P$1.0 g/g achieved BP#125/
75 mmHg.
Renal outcomes according to TA-P
As shown in Table 3, 60 (12.0%) patients reached a 50% decline
in eGFR during follow-up. In addition, 34 (6.8%) patients
Table 2. Changes in eGFR, CKD stage, proteinuria, and blood pressure.
Diagnosis Last follow up P-value
eGFR (ml/min per 1.73 m2) 87.3628.5 76.9632.8 ,0.001
CKD stage (n, %)
$90 241 (48.2%) 202 (40.4%)
60–89 162 (32.4%) 158 (31.6%)
30–59 84 (16.8%) 84 (16.8%) ,0.001
15–29 13 (2.6%) 19 (3.8%)
,15 0 (0.0%) 37 (7.4%)
Proteinuria (g/g) (n, %) 0.9 (0.4–1.8) 0.4 (0.1–1.0) ,0.001
,0.3 130 (26.0%) 229 (45.8%)
0.3–0.99 226 (45.2%) 147 (29.4%) ,0.001
1.0–2.99 130 (26.0%) 88 (17.6%)
$3.0 14 (2.8%) 36 (7.2%)
Hypertension (yes; n, %) 122 (24.4%) 178 (35.6%)
SBP (mmHg) 136.7618.2 130.1614.5 0.001
DBP (mmHg) 84.0611.9 81.8610.9 0.09
Hypertension developed during follow-up (n, %) - 56 (11.2%)
Hypertension (no; n, %) 378 (75.6%) 322 (64.4%)
SBP (mmHg) 122.7612.9 117.669.8 ,0.001
DBP (mmHg) 76.5610.2 73.467.7 ,0.001
Among patients with hypertension
TA-P,1.0 g/g (n, %) - 110 (61.8%)
TA-P$1.0 g/g (n, %) - 68 (38.2%)
BP controlled (n, %)
#130/80 mmHg - 87 (48.9%)
#130/80 mmHg (TA-P,1.0 g/g) - 61 (55.5%)
#125/75 mmHg (TA-P$1.0 g/g) - 12 (17.6%)
Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; TA-P, time-averaged
proteinuria.
doi:10.1371/journal.pone.0101935.t002
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developed ESRD. There was no patient who progressed to ESRD
before reaching a 50% decline in eGFR. In addition, no death
occurred before ESRD developed.
We further analyzed renal outcomes according to TA-P. A 50%
decline in eGFR was most commonly reached in patients with TA-
P$3.0 g/g (64.3%), followed by those with TA-P of 1.0–2.99 g/g
(33.8%). There was no significant difference in the development of
a 50% decline in eGFR between patients with TA-P,0.3 g/g
(0.8%) and those with TA-P of 0.3–0.99 g/g (2.7%) (P=0.22).
ESRD occurred in 8 (57.1%) and 26 (20.0%) patients with TA-P$
3.0 g/g and 1.0–2.99 g/g, respectively, whereas it did not occur in
any patients with TA-P,1.0 g/g. A Kaplan–Meier curve also
showed that renal survival rates were lower as patients had greater
TA-P (Figure 2), particularly from TA-P.1.0 g/g. There was no
significant difference in renal survival rate between patients with
TA-P,0.3 g/g and TA-P of 0.3–0.99 g/g. Their 10-year survival
rates were excellent, which were 99.0% and 97.9%, respectively
(P=0.171).
Multivariable Cox models for renal outcome of a 50%
decline in eGFR
To determine HRs according to TA-P groups, we constructed
multivariable Cox models where the four TA-P groups were
entered after adjustment for clinical parameters and pathologic
findings (Table 4). The risk of reaching a 50% decline in eGFR did
not differ between patients with TA-P,0.3 g/g and those with
TA-P of 0.3–0.99 g/g in model 1 adjusted for age, mean arterial
pressure, the presence of hypertension, and eGFR (HR, 3.45; 95%
CI, 0.41 to 28.80; P=0.25). The HR was not significantly altered
by addition of pathologic findings to model 1 (HR, 2.93; 95% CI,
0.35 to 24.98; P=0.33) (Table 4, Model 2). Furthermore, the
model that was fully adjusted for the use of RAS blockers and
corticosteroids showed no significant increase in the risk of
reaching a 50% decline in eGFR in patients with TA-P of 0.3–
0.99 g/g, versus those with TA-P,0.3 g/g (HR, 2.82; 95% CI,
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Figure 2. The Kaplan–Meier renal survival curve of patients
with IgAN according to time averaged proteinuria (TA-P). Renal
survival rates were lower as patients had greater amount of TA-P,
particularly from TA-P.1.0 g/g. There was no significant difference in
renal survival rate between patients with TA-P,0.3 g/g and TA-P of
0.3–0.99 g/g.
doi:10.1371/journal.pone.0101935.g002
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0.32 to 24.72; P=0.35) (Table 4, Model 3). When ARR score was
entered in the model instead of presence of hypertension, and
MEST score, we produced the same results (HR, 2.60; 95% CI,
0.30 to 22.91; P=0.388; data not shown). Of note, risk of
progression was markedly increased in patients with TA-P of 1.0–
2.99 g/g and highest in patients with TA-P.3.0 g/g. Such
increased risks in these groups were consistently noted in all three
models.
Proteinuria reduction and renal outcome
We further evaluated renal outcomes of patients categorized
according to initial proteinuria and TA-P (Table 5). Among 267
patients with baseline UPCR,1.0 g/g, 113, 123, and 31 patients
had TA-P of ,0.3, 0.3–0.99, and $1.0 g/g, respectively. There
was no significant difference in the development of a 50% decline
in eGFR between patients with TA-P,0.3 g/g and those with
TA-P of 0.3–0.99 g/g. However, compared to these two groups, 6
(19.4%) patients with TA-P.1.0 g/g reached a 50% decline in
eGFR (P,0.001). In addition, among 233 patients with baseline
UPCR$1.0 g/g, 17, 103, and 113 patients had TA-P of ,0.3,
0.3–0.99, and $1.0 g/g, respectively. There were no patients with
TA-P of ,0.3 g/g who reached a 50% decline in eGFR. In
addition, only 5 (4.9%) patients among the group with TA-P of
0.3–0.99 g/g reached this endpoint. However, 47 (41.6%) patients
with TA-P$1.0 g/g reached a 50% decline in eGFR (P,0.001). A
Kaplan-Meier curve also showed that the 10-year renal survival
rates were comparable between patients with TA-P of ,0.3 g/g
and those with TA-P of 0.3–0.99 g/g irrespective of their baseline
UPCR. However, if patients had TA-P$1.0 g/g during follow-up,
their 10-year survival rates were significantly decreased even if
they had a baseline UPCR,1.0 g/g (Figure 3).
Furthermore, the effect of proteinuria reduction was consistently
seen across the ARR scores (Table 5). Interestingly, among
patients with baseline UPCR,1.0 g/g and ARR=0, 3 (16.7%)
patients who achieved TA-P$1.0 g/g reached a 50% decline in
eGFR. Conversely, a 50% decline in eGFR occurred in only 2
(1.2%) patients with TA-P,1.0 g/g (P=0.001). In addition,
among patients who had baseline UPCR$1.0 g/g and ARR
score $2, but failed to achieve TA-P,1.0 g/g, a 50% decline in
eGFR occurred in 31 (48.4%) and 13 (61.9%) patients with
ARR=2 and 3, respectively. In contrast, only 2 patients from each
group with ARR=2 (3.6%; P,0.001) and ARR=3 (14.3%;
P=0.039) reached a 50% decline in eGFR if a TA-P,1.0 g/g was
attained.
Slopes of eGFR among the four TA-P groups
We also compared rates of renal function decline between the
four TA-P groups. The eGFR slope was the lowest in patients with
TA-P,0.3 g/g, which was significantly lower than in patients with
TA-P of 0.3–0.99 g/g (20.4161.68 vs. 20.7362.82 ml/min/
1.73 m2/year, P=0.03). Moreover, renal function of patients with
TA-P of 1.0–2.99 g/g and $3.0 g/g deteriorated faster at rates of
24.0766.54 and 29.35613.1 ml/min/1.73 m2/year, respective-
ly (P,0.001) (Table 6).
Discussion
This study aimed to determine the optimal target of proteinuria
reduction in patients with IgAN. We showed that patients with
TA-P,1.0 g/g had favorable outcomes and risk of progression
was comparable between patients with TA-P,0.3 g/g and those
with TA-P of 0.3–0.99 g/g. However, the rate of kidney function
Table 4. Multivariable Cox regression models for renal outcome of decline in eGFR.50%.
Model 1 Model 2 Model 3
Variables HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age (1 year) 0.97 (0.95 to 1.00) 0.030 0.98 (0.95 to 1.01) 0.90 0.98 (0.95 to 1.03) 0.083
eGFR (1 ml/min/1.73 m2) 0.97 (0.96 to 0.98) ,0.001 0.98 (0.97 to 0.99) ,0.001 0.98 (0.97 to 0.99) ,0.001
TA_MAP (1 mmHg) 1.03 (0.98 to 1.08) 0.22 1.04 (0.99 to 1.09) 0.13 1.04 (0.99 to 1.09) 0.17
Hypertension (vs. no) 1.23 (0.69 to 2.20) 0.48 0.95 (0.52 to 1.78) 0.88 0.97 (0.52 to 1.80) 0.97
TA-P (g/g)
,0.3 reference reference reference
0.3 to 0.99 3.45 (0.41 to 28.80) 0.25 2.93 (0.35 to 24.98) 0.33 2.82 (0.32 to 24.72) 0.35
1.0 to 2.99 47.28 (6.38 to 350.15) ,0.001 26.59 (3.48 to 203.34) 0.002 25.0 (3.17 to 197.0) 0.002
$3.0 406.35 (49.30 to 3349.18) ,0.001 288.86 (34.03 to 2451.86) ,0.001 244.07 (27.09 to
2198.88)
,0.001
Pathologic findings
M1 (vs. M0) - - 1.30 (0.64 to 2.66) 0.47 1.33 (0.65 to 2.75) 0.44
E1 (vs. E0) - - 0.97 (0.43 to 2.17) 0.94 0.94 (0.42 to 2.11) 0.87
S1 (vs. S0) - - 1.05 (0.59 to 1.88) 0.86 1.01 (0.56 to 1.82) 0.97
T1 (vs. T0) - - 2.78 (1.29 to 5.99) 0.009 2.81 (1.29 to 6.11) 0.009
T2 (vs. T0) - - 4.27 (1.80 to 10.17) 0.001 4.35 (1.81 to 10.42) 0.001
Treatment
RAS blockers (vs. no) - - - - 1.11 (0.30 to 4.06) 0.88
Corticosteroids (vs. no) - - - - 1.37 (0.65 to 2.88) 0.41
Abbreviations: HR, hazard ratio; eGFR, estimated glomerular filtration rate; TA-MAP, time-averaged mean arterial pressure; TA-P, time-averaged proteinuria; RAS, renin-
angiotensin system.
doi:10.1371/journal.pone.0101935.t004
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decline was significantly greater in patients with TA-P of 0.3–
0.99 g/g than in patients with TA-P,0.3 g/g. These findings
suggest that proteinuria reduction to ,1.0 g/day suggested by the
KDIGO guideline [18] is acceptable, but the ultimate therapeutic
goal of proteinuria reduction for renoprotection in IgAN can be
modified.
Proteinuria has long been not only a marker of kidney damage
but a therapeutic target in the management of various kidney
diseases. In diabetic nephropathy, albuminuria is the first clinical
sign of diabetic kidney injury. Many studies have consistently
shown that improved renal outcome is concordant with the
reduction in proteinuria achieved using RAS blockers in patients
with overt diabetic nephropathy [19–21]. A similar effect of
reducing proteinuria is also evident in non-diabetic kidney diseases
[22,23]. Not surprisingly, proteinuria is considered a modifiable
risk factor for kidney disease progression. However, excluding
some glomerulonephritides which are well responsive to immu-
nosuppressive drugs or undergo spontaneous remission, it is
difficult to achieve complete resolution of proteinuria. Moreover,
the optimal target for proteinuria reduction to halt progression of
kidney disease is unknown.
To date, it has been suggested that proteinuria should be
decreased to ,1.0 g/day in IgAN because risk of progression
increases markedly beyond this point [18,24,25]. Using the
Toronto Glomerulonephritis Registry, Reich et al. reported that
renal survival was similar in patients with TA-P,0.3 g/day and
those with TA-P of 0.3–1.0 g/day [11]. A recent Spanish study of
141 IgAN patients with minor abnormalities at presentation also
supported this finding because TA-P.0.5 g/day was not associ-
ated with an increased risk of developing a .50% increase in
baseline serum creatinine levels in the adjusted multivariable
analysis compared to TA-P#0.5 g/day [26]. In keeping with
findings of these studies, we showed that there was no difference in
renal events between patients with TA-P,0.3 g/g and those with
TA-P of 0.3–0.99 g/g. Only 7 (2.0%) patients with TA-P,1.0 g/g
developed a 50% decline in eGFR and none of them reached
ESRD during follow-up. Their 10-year survival rates were
excellent. Furthermore, risk of reaching a 50% decline in eGFR
was comparable between patients with baseline proteinuria $
1.0 g/g who achieved TA-P,1.0 g/g and patients with TA-P,
1.0 g/g throughout the follow-up period. These findings together
suggest that the cut-off level of proteinuria reduction suggested by
the current guideline is reasonable.
Moreover, these findings were consistently observed across all
risk groups. We evaluated risk of progression using the ARR. As
seen in table 5, irrespective of the ARR score, more patients who
failed to achieve TA-P,1.0 g/g reached primary endpoint
compared to those who achieved this goal. Interestingly, the effect
of proteinuria reduction appears to exist even in high risk patients.
There were only 4 patients with TA-P,1.0 g/g who developed a
50% decline in eGFR although they had baseline proteinuria $
1.0 g/g and ARR$2. These findings further underscore the
importance of proteinuria reduction ,1.0 g/g in the management
of IgAN.
On the other hand, there has been emerging concern about
whether further reduction of proteinuria below the level the
current guideline suggests is required. In a Chinese cohort study
by Le et al. [12], TA-P of 0.5–1.0 g/day were associated with a
9.1-fold increased risk of progression compared to TA-P,0.5 g/
day. In addition, rate of eGFR decline was greater in patients with
TA-P of 0.5–1.0 g/day. Unfortunately, tubulointerstitial fibrosis
and glomerulosclerosis, which are widely accepted as the most
important pathologic factors affecting renal outcome, were not
evaluated in their study. In contrast, the Spanish cohort study and
the present study incorporated pathologic findings in the
multivariable analyses and these two studies did not find a
significant risk reduction of developing adverse renal events
conferred by further lowering proteinuria among patients with
TA-P,1.0 g/day or 1.0 g/g. However, in our study, there were
slightly more patients with TA-P of 0.3–0.99 g/g who developed a
50% decline in eGFR than those with TA-P,0.3 g/g (2.7% vs.
0.8%, P=NS) and the former group had a trend towards a higher
risk of reaching the primary outcome although these did not reach
statistical significance. In addition, from a viewpoint of eGFR
slope, our findings are in agreement with the Chinese cohort
study. In fact, the Oxford MEST score was higher in patients with
TA-P of 0.3–0.99 g/g than in those with TA-P,0.3 g/g. This
higher frequency of pathologic lesions in the former group might
result in a greater slope of eGFR decline than in the latter group,
although the annual eGFR decline was20.73 ml/min/1.73 m2 in
patients with TA-P of 0.3–0.99 g/g, which is considered
acceptable in management of patients with chronic kidney disease.
However, given the slowly progressive nature of IgAN and young
age at the time of diagnosis, this difference in eGFR slope between
patients with TA-P of 0.3–0.99 g/g and those with TA-P,0.3 g/g
may lead to difference in long-term prognosis. Of note, in both
Chinese cohort study and our study, patients with minimal TA-P
rarely progress; their eGFR slopes were only 20.4 ml/min/
1.73 m2/year. These findings suggest a potential renoprotective
benefit of further lowering proteinuria ,0.3 g/g or ,0.5 g/day to
halt progression of IgAN.
The present study also partly supports the previous findings that
the target for proteinuria reduction differs depending on the type
Figure 3. The Kaplan–Meier renal survival curve of patients
with IgAN according to baseline urine protein-to-creatinine
ratio (UPCR) and time-averaged proteinuria (TA-P). The 10-year
renal survival rates were comparable between patients with TA-P of ,
0.3 g/g and those with TA-P of 0.3–0.99 g/g irrespective of their
baseline UPCR. However, if patients had TA-P$1 g/g during follow-up,
their 10-year survival rates were significantly decreased even if they had
a baseline UPCR,1.0 g/g.
doi:10.1371/journal.pone.0101935.g003
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of proteinuric glomerular diseases [14,27]. In other glomerulone-
phritides such as membranous nephropathy (MGN) or focal
segmental glomerulosclerosis, patients with proteinuria of 1.0–
2.0 g/day had similar eGFR decline rate to those with proteinuria
of 0.5–1.0 g/day [14]. In particular, the rate of decline of eGFR in
patients with MGN who had proteinuria ,3.5 g/day was only 2
0.93 ml/min/1.73 m2/year and 12.0% of these patients devel-
oped a 50% decrease in creatinine clearance during a median
follow-up of 82 months [27]. In contrast, in the Toronto study by
Reich et al, renal survival sharply began to decline as TA-P
increased from 1.0–2.0 g/day in patients with IgAN [11]. This
finding was corroborated by our study showing that the risk of
reaching a 50% decline in eGFR began to increase markedly as
TA-P rose above 1.0 g/g. The 10-year renal survival rate of
patients with TA-P,1.0 g/g was .90% and none of these
patients developed ESRD, whereas that of patients with TA-P of
1.0–2.99 g/g was 47.7% and 20.0% developed ESRD. Therefore,
unlike other types of glomerulonephritis in which subnephrotic
proteinuria is not associated with higher risk of loss of kidney
function, aggressive treatment to lower proteinuria to 1.0 g/g can
be justified in patients with IgAN.
Several shortcomings of this study should be discussed. First,
effects of therapeutic interventions such as RAS blockers or
corticosteroids could not be accurately assessed due to retrospec-
tive nature of our study. The KDIGO guideline suggests the use of
corticosteroids in patients with persistent proteinuria .1.0 g/day
and preserved kidney function [18,28,29]. In this study, cortico-
steroids were prescribed in 56 (11.2%) patients. Of note, 6 (4.6%)
and 25 (11.1%) patients with TA-P,0.3 g/g and 0.3–0.99 g/g
received corticosteroids, respectively. 23 (74.2%) of these patients
initially had persistent proteinuria .1.0 g/g, despite optimized
supportive care for at least 3 months and the remaining 8 (25.8%)
showed nephrotic syndrome at presentation. All these patients
responded to corticosteroids and achieved a favorable outcome.
Although this finding may favor the use of corticosteroids, it was
not associated with an improved renal outcome in the fully
adjusted multivariable model. More well-designed prospective
studies are required to validate the effect of corticosteroids.
Second, we used UPCR for the measurement of proteinuria
instead of 24-h urine collection, the gold standard method to assess
proteinuria. In fact, there was a significant difference between
baseline 24-h proteinuria and UPCR as seen in table 1.
Unfortunately, 24-h urine collection was not feasible at all visits
and is usually repeated only when proteinuria substantially
increases. Because UPCR is easily performed in the outpatient
setting and can be reliably used to monitor proteinuria [30], our
institution performs UPCR at every visit instead of 24-h urine
collection. Therefore, in this study, calculating TA-P based on
UPCR more accurately reflected the average proteinuria during
the follow-up period. Finally, our median follow-up duration was
65 months, which is shorter than in previous studies [11,26].
During this period, ESRD, a ‘hard’ endpoint, did not occur in
patients with proteinuria ,1.0 g/g and thus it is not feasible to
evaluate whether this outcome may differ between patients with
TA-P,0.3 g/g and those with TA-P of 0.3–0.99 g/g. In addition,
only 7 patients with TA-P,1.0 g/g reached a 50% decline in
eGFR. Such small number of events might not have adequate
statistical power to see the difference in the study endpoints. As
aforementioned, patients with TA-P of 0.3–0.99 g/g had a higher
Oxford-MEST score and a greater decline rate of renal function
than patients with TA-P,0.3 g/g although eGFR slope in the
former group was .21.0 ml/min/1.73 m2/year. Because IgAN
has slowly progressive nature, a longer period of observation is
required to evaluate whether more renal events will occur in
patients with moderate proteinuria.
Conclusions
This study showed that the risk of developing adverse renal
events was comparable between patients with TA-P,0.3 g/g and
those with TA-P of 0.3–0.99 g/g. In addition, irrespective of initial
proteinuria, their renal outcome was favorable if they achieved
TA-P,1.0 g/g. However, patients with TA-P of 0.3–0.99 g/g had
a greater slope of eGFR decline than those with TA-P,0.3 g/g.
These findings suggest that primary therapeutic target of
proteinuria reduction is ,1.0 g/g, but the ultimate optimal goal
can be lowered to ,0.3 g/g to halt progression of IgAN. Further
long-term studies are required to clarify whether proteinuria
reduction to ,0.3 g/g may confer better renal outcomes.
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